Optimal dose of centchroman in management of cyclical mastalgia
Phase 2
- Conditions
- Health Condition 1: M95-M95- Other disorders of the musculoskeletal system and connective tissue
- Registration Number
- CTRI/2024/08/072215
- Lead Sponsor
- ttar Pradesh University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All women with mastalgia with VAS score =3 lasting for more than 5-7 days per cycle were included after signing a consent form.
Exclusion Criteria
•Patients with polycystic ovarian diseases and uterine cervical hyperplasia.
•First six months of Lactation and pregnancy
•Patients who were not giving consent.
•Past history of breast carcinoma or family history of breast carcinoma
•Patient who were planning for pregnancy .
•Women suspected or diagnosed of malignancy
•Recent history of jaundice or hepatic impairment.
•Severe allergic states.
•History of thrombosis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptomatic relief from cyclical mastalgia.Timepoint: Outcome will be assessed at 4,8,12 and 24 weeks
- Secondary Outcome Measures
Name Time Method Improvement in fibroadenosis as well as reduction in size of fibroadenoma.Timepoint: Outcome will be assessed at 4,8,12 & 24 weeks